ETX-155

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

ETX-155 is a GABA A receptor positive allosteric modulator and neurosteroid which is or was under development for the treatment of depressive disorders, seizures, and fibromyalgia. It is taken orally and has an elimination half-life of 24 to 40 hours. The drug produces antidepressant-like, anxiolytic-like, and anticonvulsant effects in rodents. Side effects of ETX-155 in humans include somnolence, fatigue, dizziness, and headache. ETX-155 was originated by Athenen Therapeutics and is or was under development by Climb Bio and/or Eliem Therapeutics. As of October 2024, development of the drug for all indications has been suspended or discontinued. It reached phase 1 clinical trials prior to the suspension or discontinuation of its development.

ETX-155 is a GABA A receptor positive allosteric modulator and neurosteroid which is or was under development for the treatment of depressive disorders, seizures, and fibromyalgia. It is taken orally and has an elimination half-life of 24 to 40 hours. The drug produces antidepressant-like, anxiolytic-like, and anticonvulsant effects in rodents. Side effects of ETX-155 in humans include somnolence, fatigue, dizziness, and headache. ETX-155 was originated by Athenen Therapeutics and is or was under development by Climb Bio and/or Eliem Therapeutics. As of October 2024, development of the drug for all indications has been suspended or discontinued. It reached phase 1 clinical trials prior to the suspension or discontinuation of its development.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1372018964 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

4 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.